BioCryst Pharmaceuticals
BCRX
BioCryst Pharmaceuticals (BCRX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.30
- EPS estimate
- $0.15
- EPS surprise
- +94.55%
- Revenue surprise
- +19.08%
- Revenue
- $218.3M
- Revenue estimate
- $183.3M
- Reported
- Aug 5, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | $0.15 | $0.30 | +94.55% | $218.3M | SEC |
| Q1 2026 | May 6, 2026 | $0.04 | −$2.98 | −6826.86% | $156.4M | SEC |
| Q4 2025 | Feb 26, 2026 | $0.05 | $1.12 | +2218.84% | $406.6M | SEC |
| Q3 2025 | Nov 3, 2025 | $0.04 | $0.06 | +50.75% | $159.4M | SEC |
| Q2 2025 | Aug 4, 2025 | $0.01 | $0.02 | +185.71% | $163.4M | SEC |
| Q1 2025 | May 5, 2025 | −$0.07 | $0.00 | +100.00% | $145.5M | SEC |
| Q4 2024 | Feb 24, 2025 | −$0.05 | −$0.13 | −155.40% | $131.5M | SEC |
| Q3 2024 | Nov 4, 2024 | −$0.07 | −$0.07 | −2.94% | $117.1M | SEC |
| Q2 2024 | Aug 5, 2024 | −$0.17 | −$0.06 | +65.32% | $109.3M | SEC |
| Q1 2024 | May 6, 2024 | −$0.21 | −$0.17 | +18.78% | $92.8M | SEC |
| Q4 2023 | Feb 26, 2024 | −$0.25 | −$0.31 | −26.07% | $93.4M | SEC |
| Q3 2023 | Nov 2, 2023 | −$0.25 | −$0.19 | +22.45% | $86.7M | SEC |
| Q2 2023 | Aug 3, 2023 | −$0.23 | −$0.40 | −70.94% | $82.5M | SEC |
| Q1 2023 | May 3, 2023 | −$0.30 | −$0.28 | +6.26% | $68.8M | SEC |
| Q4 2022 | Feb 21, 2023 | −$0.17 | −$0.38 | −128.37% | $79.5M | SEC |
| Q3 2022 | Nov 1, 2022 | −$0.29 | −$0.23 | +19.44% | $75.8M | — |
| Q2 2022 | Aug 4, 2022 | −$0.34 | −$0.32 | +6.87% | $65.5M | — |
| Q1 2022 | May 5, 2022 | −$0.36 | −$0.40 | −10.34% | $49.9M | — |
| Q4 2021 | Feb 23, 2022 | −$0.30 | −$0.10 | +66.10% | $47.2M | — |
| Q3 2021 | Nov 3, 2021 | −$0.29 | −$0.33 | −12.74% | $41.0M | — |
Quarterly revenue
Frequently asked questions
When did BioCryst Pharmaceuticals (BCRX) last report earnings?
BioCryst Pharmaceuticals last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did BCRX beat earnings estimates?
Yes. BioCryst Pharmaceuticals reported EPS of $0.30 for Q2 2026 against a $0.15 estimate — a 94.55% beat.
How much revenue did BCRX report last quarter?
BioCryst Pharmaceuticals reported $218.3M in revenue for Q2 2026, against a consensus estimate of $183.3M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.